Oxford Biomedica plc, one of the companies in the consortium that developed the Oxford Covid vaccine, has announced the appointment of Leone Patterson as an independent non-executive director. She will join the board of the biotech CDMO (contract development and manufacturing organisation) next week.
Patterson has more than 20 years’ public company biotech experience, including in the cell and gene therapy industry. She has worked across areas including strategy, finance, operations and governance,
Currently chief financial and business officer at NASDAQ-listed Tenaya Therapeutics, a company researching therapies for heart disease, Patterson also sits on the board of another clinical-stage company: Nkarta.
Patterson has previously held senior roles at Adverum Biotechnologies, Diadexus and Transcept Pharmaceuticals. Earlier in her career, she worked within Novartis, Chiron and KPMG.
Dr Roch Doliveux, chair of Oxford Biomedica, said: “The appointment of Leone comes at an important juncture for Oxford Biomedica, as we advance our global leadership in viral vector development and supply, providing innovative solutions to our international biopharma customers. Leone’s deep understanding of corporate finance, her experience of the US public markets and M&A, in addition to her extensive experience in the cell and gene therapy industry will be invaluable in supporting our international strategy and further strengthening our market position.”